NewAmsterdam triumphs in first Phase III trial of cholesterol …

Jul 30, 2024 · NewAmsterdam triumphs in first Phase III trial of cholesterol-busting drug. ... oral option that can potentially transform the treatment landscape.” The drug remained well …

CouponFollow Extension

2%
OFF

NewAmsterdam Pharma Dives Despite Cholesterol Treatment …

3 weeks from now

Nov 20, 2024 · The company's combination of drugs called obicetrapib and ezetimibe reduced LDL cholesterol by an average 52.2% after 84 days. At the median, the reduction was 54%. …

investors.com

$481
OFF

NewAmsterdam Pharma: Cholesterol Drug Treatment With …

3 weeks from now

Jul 5, 2024 · NewAmsterdam Pharma Company had cash of $481.1 million as of March 31, 2024. Read why I feel NAMS is an interesting biotech stock to look into.

seekingalpha.com

41%
OFF

NewAmsterdam Leaps On Positive Trial Results | The Pharmaletter

3 weeks from now

Dec 11, 2024 · Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. …

thepharmaletter.com

6%
OFF

NewAmsterdam Pharma Announces Positive Data For Its …

3 weeks from now

The treatment discontinuation rate for the obicetrapib arm was 7.6% versus 14.4% for placebo. ... More on NewAmsterdam Pharma. NewAmsterdam Pharma: Cholesterol Drug Treatment With …

msn.com

42%
OFF

Biotech Stock: NewAmsterdam Cholesterol Drug Study Results Fall …

3 weeks from now

Jul 29, 2024 · NewAmsterdam Pharma said Monday its experimental drug lowered "bad" LDL cholesterol by almost 42% over a year, but the results were slightly below expectations.The …

investors.com

35%
OFF

Novo Nordisk And Eli Lilly Rival Soars 35% After Promising ... - CNBC

3 weeks from now

Feb 26, 2024 · Zealand Pharma's Phase 2 trial was an "uniquivocal win" for a drug that can treat both liver disease and obesity, analysts said.

cnbc.com

22%
OFF

Novo Nordisk's Next-gen Obesity Treatment Hits Target In Early Study

3 weeks from now

Jan 24, 2025 · Novo said that patients on a high dose of the injectable form of the drug, called amycretin, lost 22% of their weight after 36 weeks, when analyzing the effects if all people …

statnews.com

FAQs about NewAmsterdam triumphs in first Phase III trial of cholesterol … Coupon?

Does newamsterdam Pharma's cholesterol drug lower cardiovascular risk?

NewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events and the biotech stock catapulted. ...

Does Amsterdam Pharma's cholesterol drug lower risk of heart attacks?

N ewAmsterdam Pharma said Tuesday its cholesterol drug lowered the risk of major cardiovascular events — like a heart attack or stroke — and the biotech stock catapulted. Please watch the video at Investors.com - How To Buy Stocks: Cup With Handle Chart Pattern ...

Does newamsterdam's obicetrapib lower cardiovascular risk?

NewAmsterdam Pharma (NAMS) said Tuesday its cholesterol drug lowered the risk of major cardiovascular events — like a heart attack or stroke — and the biotech stock catapulted. Over the course of a year, patients who received NewAmsterdam's obicetrapib had a 21% lower risk of having a major cardiovascular event, the company said in a news release. ...

What happened to newamsterdam stock?

NewAmsterdam stock skyrocketed 41.4% to close at 26.19. Shares opened at their highest point since November 2022. The biotech stock broke out of a buy point at 25.32 out of a cup-with-handle base, according to MarketSurge. NewAmsterdam tested obicetrapib in patients who don't have controlled LDL cholesterol. ...

Is newamsterdam Pharma (NAMS) a good biotech?

Learn More » NewAmsterdam Pharma Company N.V. ( NASDAQ: NAMS) is a biotech that should be on all traders and investors' radar. The reason why I state that is because it is gearing up to report data from several studies over the next 1-year period. ...

Is newamsterdam a promising agent for dyslipidemia?

According to GlobalData, NewAmsterdam’s therapy has the potential to address the treatment gap and is projected to be the most promising agent in the dyslipidemia market by 2032. ...